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Genetic or pharmacological ablation of toll-like receptor 2 (TLR2) protects against myocardial ischemia/reperfusion injury (MI/R).
However, the endogenous ligand responsible for TLR2 activation has not yet been detected.Theobjective of this studywas to identify
HMGB1 as an activator of TLR2 signalling during MI/R. C57BL/6 wild-type (WT) or TLR2−/−-mice were injected with vehicle,
HMGB1, or HMGB1 BoxA one hour before myocardial ischemia (30min) and reperfusion (24 hrs). Infarct size, cardiac troponin T,
leukocyte infiltration,HMGB1 release, TLR4-, TLR9-, andRAGE-expressionwere quantified. HMGB1 plasma levels weremeasured
in patients undergoing coronary artery bypass graft (CABG) surgery. HMGB1 antagonist BoxA reduced cardiomyocyte necrosis
duringMI/R inWTmice, accompanied by reduced leukocyte infiltration. Injection ofHMGB1did, however, not increase infarct size
in WT animals. In TLR2−/−-hearts, neither BoxA nor HMGB1 affected infarct size. No differences in RAGE and TLR9 expression
could be detected, while TLR2−/−-mice display increased TLR4 and HMGB1 expression. Plasma levels of HMGB1 were increased
MI/R in TLR2−/−-mice after CABG surgery in patients carrying a TLR2 polymorphism (Arg753Gln). We here provide evidence
that absence of TLR2 signalling abrogates infarct-sparing effects of HMGB1 blockade.
1. Introduction
Toll-like receptors being the most prominent class of innate
immunity receptors are the first line of defence against invad-
ing pathogens. Beyond host defence, these receptors also have
a role in the majority of sterile inflammatory conditions. We
and others have shown that antibody blockade [1], pharmaco-
logical preconditioning [2, 3], or genetic ablation [4, 5] of toll-
like receptor 2 (TLR2) signalling is protective in a mouse
model of myocardial ischemia and reperfusion (MI/R). The
underlying mechanisms reported so far include augmented
phosphoinositide-3-kinase/Akt signalling, increased preser-
vation of Connexin 43 gap junctions, reduced proapoptotic
signalling, reduced proinflammatory cytokine, and chemok-
ine release with subsequently reduced leukocyte infiltration
[1–5]. It is, however, unclear which of its proposed endoge-
nous ligand(s) causes TLR2 activation in the setting of MI/R.
High mobility group box 1 (HMGB1) as a nuclear protein
has two DNA-binding domains and is involved in stabiliza-
tion of nucleosomes and regulation of gene expression [6].
As a cytosolic protein it is involved in the promotion of
autophagy [7], and as an extracellular protein it is either pas-
sively released from necrotic cells [8] or actively secreted by
immune cells upon proinflammatory stimulation [9]. Since
HMGB1 release elicits or augments inflammatory reactions
[10, 11] it was often regarded as the prototype damage
associated molecular pattern (DAMP, as opposed to PAMP,
pathogen associated molecular patterns, which are typical
TLR ligands). This view has however changed, when in a
number of studies highly purified HMGB1 failed to exert
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proinflammatory cytokine-like functions (reviewed in [12]).
It was therefore concluded that HMGB1 might act as a chap-
erone potentiating or modulating the effects of proinflamma-
tory mediators.
A role for HMGB1 in MI/R was established in a study
by Andrassy et al. that, in line with the proinflammatory,
cytokine concept for HMGB1 showed increased myocardial
damage when HMGB1 was administered and decreased
necrosis when HMGB1 was competitively blocked by its
nonfunctional fragment Box A [13]. Both effects could not
be observed in the absence of the receptor for advanced
glycation end products (RAGE), whichwas the first identified
receptor for HMGB1 in neuritis and macrophages [14, 15].
However, besides RAGE, other receptors including TLR2,
TLR4, and TLR9 have been identified as HMGB1 receptors
[16–18], and the utilization of these receptors might be largely
different between cell types and tissues [19].
In the present study, we therefore tested the hypothesis
that administration or pharmacological blockade of HMGB1
affects myocardial injury after MI/R and that these effects are
dependent on TLR2. Besides its putative adverse effects in
MI/R, itmust be noted, that during recovery frommyocardial
infarction exogenous HMGB1 injection has been shown in
a number of studies to prevent adverse remodelling and
improve cardiac function [20–22]. The present preclinical
study was, however, conducted to identify HMGB1 as a
ligand/cofactor responsible for TLR2 activation during the
acute phase of MI/R.
There is a high frequency of heterozygous carriers of a
nonfunctional TLR2 polymorphism (Arg753Gln) in the Cau-
casian population [23]. Carriers of the Arg753Gln mutation
are at a higher risk for coronary restenosis after percutaneous
transluminal coronary angioplasty (PTCA) [24]. To identify
a possible relation between HMGB1 release and presence of
the Arg753Gln polymorphism in MI/R we quantified serum
HMGB1 concentrations in patients undergoing elective coro-
nary artery bypass graft (CABG) surgery. Patients had been
recruited for a trial investigating toll-like receptor polymor-
phisms in cardiac surgery. A subgroup analysis was per-
formed in carriers of the Arg753Gln polymorphism undergo-
ing elective CABG surgery, which were compared to age- and
sex-matched controls from the study collective.
2. Materials and Methods
2.1. Animals. Male C57BL/6JRjWildtype (WT) and TLR2−/−
mice (B6.129-TLR2tm1kir/J, The Jackson Laboratories, Bar
Harbor, Maine, USA), back-crossed to the C57BL/6J-
background for 9 generations, were used. The age of animals
used in this study ranged between 5 and 7 months. The ani-
mals were housed under specified pathogen-free conditions
and had access to standard laboratory animal chow andwater
ad libitum. All procedures were performed in accordance
with the Guide for the Care and Use of Laboratory Animals
published by the United States National Institutes of Health
and were approved by the local government authorities
(approval reference number F91/53, Regierungspra¨sidium
Darmstadt, Germany).
2.2. Myocardial Ischemia/Reperfusion (MIR). Experimental
myocardial ischemia was performed as described previously
[25, 26]. Mice were anesthetized with an intraperitoneal
(i.p.) injection of pentobarbital (Narcoren 90mg/kg, Merial
GmbH, Hallbergmoos, Germany). For analgesia animals
received buprenorphine s.c. (0.05mg/kg) before and 8 hrs
after the intervention. Mice were orally intubated and ven-
tilated using a MiniVent (Hugo Sachs Elektronik-Harvard
Apparatus,March-Hugstetten, Germany) with a tidal volume
of 9 𝜇L/g bodyweight and a frequency of 110/min. FiO2 was
set to 0.5. The front aspect of the heart was visualized by a
left thoracotomy in the 4th intercostal space.The left anterior
descending (LAD) coronary artery was ligated using 7-0
suture (Seralene, Serag-Wiessner, Naila, Germany), the ends
of which were passed through a short PE tube, pulled
tight, and held into place by a microserrefine. Ischemia was
confirmed by the myocardium turning notably pale. After 30
minutes of ischemia, tension of the thread was released and
reperfusion was confirmed visually. After wound closure ani-
mals were weaned from the respirator. The tracheal tube was
removed once spontaneous breathing was sufficient. Oxygen
was administered via a facemask until animals spontaneously
removed themselves from the ventilator. After 24 hours of
reperfusion, animals were anesthetized as described above.
Blood was taken from the inferior caval vein with a hep-
arinised syringe, the ligation was retightened, and EvansBlue
dye (Sigma-Aldrich, Munich, Germany) was injected via the
right ventricle.
Animalswere injected i.p. one hour prior to ischemiawith
either Vehicle (Veh, 5%DMSO in phosphate buffered saline),
HMGB1 Box A (300 𝜇g, LPS-free, HMGBiotech, Milano,
Italy) or recombinant HMGB1 (600 𝜇g, LPS-free, eBiosci-
ence, Frankfurt, Germany).
2.3. Infarct Size Determination. Evans Blue-stained hearts
were excised and immediately cut into five equal slices.
Pictures of these slices were taken before and after incubation
with p-nitro blue tetrazolium (0.5%, 25min, 37∘C, Sigma-
Aldrich, Munich, Germany). Infarct size (IS) and area at risk
(AR) were planimetrically quantified using SigmaScan Pro
image measurement software (SPSS Inc., Chicago, IL, USA).
2.4. Cardiac Troponin T. Blood samples were centrifuged
for 7 minutes at 7000×g. Plasma was stored at −80∘C
until assayed. Samples were diluted 1 : 10 in whole blood of
untreatedWT animals and cardiac troponin Twas quantified
using the Cardiac Reader (Roche, Mannheim, Germany),
according to the manufacturer’s instructions.
2.5. Leukocyte Count. Leukocyte infiltration was quantified
in paraformaldehyde-embedded 5𝜇m sections stained with
hematoxylin and eosin (H&E). For each animal 10 micro-
scopic fields with amagnification of 20x, covering 3.2mm2 of
the area at risk were analyzed.
2.6. Real-Time rt-PCR. Real-Time PCR was performed using
SYBRGreen incorporation on a StepOnePlus Real-Time PCR
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Table 1: Patient demographics.
Control Arg753Gln 𝑃
𝑛 10 5
Male 9/10 5/5 NS
Age 69.5 (48–80) 66.0 (53–79) NS
BMI 30.5 (24.4–33.9) 27.0 (23.5–32.9) NS
Duration of surgery (min) 249.5 (180.0–320.0) 225.0 (170.0–270.0) NS
Cardiopulmonary bypass time (min) 160.5 (94.0–233.0) 123.0 (110.0–163.0) NS
Aortic cross-clamp time (min) 58.0 (30.0–82.0) 51.0 (42.0–58.0) NS
CK-MB (%CKtotal) 7.3 (2.2–23.0) 13.9 (3.8–22.8) NS
Total numbers, median (min–max), Fisher’s test, Mann-Whitney test, BMI: body mass index, CK: creatine kinase, NS: not significant.
system (Applied Biosystems, Weiterstadt, Germany) accord-
ing to themanufacturer’s instructions. Sampleswere analyzed
in duplicate. Results are presented as x-fold expression of
the ANAR of WT animals using the ΔΔCt method. Primers
used were HMGB1 (forward 5󸀠-TGC GTC TGG CTC CCG
CTCTC-3󸀠, reverse 5󸀠-AGTTGATTTTCCTCCGCGAGG
CAC-3󸀠), RAGE (forward 5󸀠- CACTTGTGCTAAGCTGTA
AGGG-3󸀠; reverse 5󸀠-CATCGACAATTCCAGTGGCTG-
3󸀠), TLR4 (forward 5󸀠-GCC TTT CAGGGAATT AAGCTC
C-3󸀠; reverse 5󸀠-GAT CAA CCG ATG GAC GTG TAA A-
3󸀠), TLR9 (forward 5󸀠-ACAACTCTGACT TCGTCCACC-
3󸀠; reverse 5󸀠-TCT GGG CTC AAT GGT CAT GTG-3󸀠), 18S
(forward 5󸀠-CAC GGG AAA CCT CAC CCGGC-3󸀠, reverse
5󸀠-CGG GTG GCT GAA CCG CCA CTT-3󸀠).
2.7. Immunohistochemistry. RAGE expression was assessed
by standard immunohistochemistry protocols using goat
antimouse primary antibody (# AF1179, R&D systems, Wies-
baden, Germany) and rabbit antigoat secondary antibody
(# HAF017, R&D systems, Wiesbaden, Germany). Antibody
binding was visualized by diaminobenzidine (DAB). DAB-
positive area was expressed as fraction of the total area of
10 microscopic fields at a magnification of 20x covering
3.2mm2.
2.8. Plasma HMGB1. Samples were analyzed by ELISA in
microtiter plates. Wells were coated with 50 𝜇L/well of anti-
HMGB1/HMG1 (Upstate Biotechnology, Lake Placid, NY)
at 1.5𝜇g/mL. Following overnight incubation at 4∘C, plates
were blocked with 1% BSA in PBS. Standard and serum
samples were added and incubated for two hours at room
temperature. After washing, 50𝜇L biotinylated anti-HMGB1
(R&D Systems, Abingdon, UK), 0.75 𝜇g/mL, was added and
incubated for one hour at room temperature. After washing,
streptavidin peroxidase was added and incubated for one
hour at room temperature. After washing, 3,3󸀠,5,5󸀠-tetrame-
thylbenzidine dihydrochloride (TMB) was added. Reactions
were stopped after 15 minutes with H
2
SO
4
(1M) and read
spectrophotometrically at 450 nm.
2.9. Patient Recruitment. The clinical trial was conducted to
investigate the role of TLR polymorphisms in cardiac surgery.
Inclusion and exclusion criteria were published elsewhere
[27]. Briefly, patients undergoing elective cardiac surgery
(coronary artery bypass graft (CABG) and/or valve surgery
(VS) including replacement and reconstruction) were
included. Inclusion criteria are as follows: patients had to
be of age 18 or older, and had elective cardiac surgery, on
cardiopulmonary bypass (CPB). Exclusion criteria are as
follows: cardiac surgery performed without CPB, history of
diseases affecting theHPA axis, or systemic or local treatment
with glucocorticoids within 30 days before surgery. The
study was approved by the local ethical review committee
(University Hospital Dusseldorf) and carried out in compli-
ance with the principles established in the Helsinki Dec-
laration and all further amendments. Written consent was
obtained. DNA was extracted from whole blood by commer-
cial kits (QIAmp, Qiagen, Hilden, Germany). Genotyping
for TLR2 SNP Arg753Gln (rs5743708) was performed by
melting curve analysis employing FRET probes and the
Lightcycler (Roche Diagnostics, Mannheim, Germany) as
described previously [28]. From the study collective 5 patients
heterozygous for the TLR2 polymorphism, Arg753Gln were
compared with 10 age- and sex-matched controls. Plasma
HMGB1 levels were determined before and on day 3 after
surgery. Patient demographics are presented in Table 1.
2.10. Statistics. Statistical analysis was performedusing Prism
software (GraphPad Software Inc., La Jolla, CA). Results are
presented as mean ± SEM of n observations. All datasets
underwent normality testing. Comparisons between groups
were made using Mann-Whitney 𝑈 or Student 𝑡-tests, where
appropriate. 𝑃 < 0.05 was considered significant.
3. Results
3.1. HMGB1 Antagonist Box A Reduced Myocardial Damage.
The area at risk (AR) relative to the area of the left ventricle
(LV) was similar in all experimental groups (Figure 1(a)).
Treatment with Box A, a nonfunctional fraction and compet-
itive antagonist of HMGB1, reduced infarct size (IS), and tro-
ponin T (TnT) plasma levels as compared to vehicle-treated
WT mice (Figures 1(b) and 1(c)). In TLR2−/− mice, which
as expected showed reduced myocardial damage after MI/R,
Box A treatment had no effect on infarct size or TnT levels.
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Figure 1: Quantification ofmyocardial damage after ischemia (30min) and reperfusion (24 hrs). (a)The area at risk relative to the left ventricle
(AR%LV)was not different between experimental groups. HMGB1 BoxA reduced (b) infarct size relative to theAR (IS%AR) and (c) Troponin
T plasma levels compared to vehicle-treated (Veh) WT animals. TLR2−/− mice showed reduced myocardial damage compared to WT mice,
whereas Box A had no protective effect in these animals. Injection with HMGB1 did not aggravate myocardial necrosis in both genotypes. (d)
Hearts perfused with EvansBlue (EB, above) were cut into five equal sections, photographed, and incubated with p-nitro-blue-tetrazolium
(NBT, below) for the quantification of AR and IS. ∗𝑃 < 0.05.
3.2. Injection with HMGB1 Did Not Aggravate Myocardial
Necrosis. Contrariwise, animals were treated with purified
HMGB1 injection to aggravate myocardial injury. However,
HMGB1 injection had no effect on infarct size or TnT levels
after MI/R in both WT and TLR2−/− (Figures 1(a) and 1(c)).
3.3. Reduced Leukocyte Infiltration after Box A Treatment.
Injection with Box A reduced leukocyte infiltration into
the AR in WT animals compared to Veh-treated controls
(Figure 2). Concomitant to its failure to aggravatemyocardial
injury, injection with purified HMGB1 did also not augment
leukocyte infiltration in WT animals. Leukocyte infiltration
in TLR2−/− was not affected by either Box A or HMGB1
treatment.
3.4. Expression Levels of HMGB1 and Its Receptors RAGE,
TLR4, andTLR9 afterMI/R. HMGB1mRNAwasmoderately
increased in the ANAR of TLR2−/− animals after MI/R as
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Figure 2: Leukocyte infiltration after myocardial ischemia (30min)
and reperfusion (24 hrs). Box A reduced leukocyte infiltration in
WT animals, while it had no effect in TLR2−/− animals. HMGB1
injection did not affect leukocyte infiltration in both WT and
TLR2−/−. ∗𝑃 < 0.05.
compared to WT (Figure 3(a)). This was accompanied by
significantly higher HMGB1 plasma levels compared to WT
(Figure 3(b)). The expression of RAGE, the main receptor
for HMGB1 in several cell types, was however not different
between genotypes (Figures 3(c) and 3(d)), neither was the
mRNA expression of TLR9 (Figure 3(e)). TLR4, another
receptor for HMGB1, showed increased mRNA expression in
TLR2−/− animals as compared to WT (Figure 3(f)).
3.5. Patients Heterozygous for the Arg753Gln TLR2 Polymor-
phism Displayed Increased HMGB1 Release after CABG Sur-
gery. No significant differences could be detected between
the carriers of the Arg753Gln polymorphism and age- and
sex-matched controls in the following variables (Table 1):
body mass index (BMI), duration of surgery, cardiopul-
monary bypass time, aortic cross-clamp time, or release of the
myocardial isoformof creatine-kinase (CK-MB) in relation to
total CK release (CK-MB [%CKtotal]).
All patients undergoing CABG surgery with extracor-
poreal circulation showed increased HMGB1 plasma levels
on day 3 after surgery as compared to baseline (Figure 4).
Induction of HMGB1 release was however significantly more
pronounced in carriers of the Arg753Gln polymorphism.
4. Discussion
The results from the present study identify a relation between
HMGB1 and TLR2-signalling in myocardial ischemia and
reperfusion.
Consistent with former observations [13], competitive
antagonism of HMGB1 via its subunit Box A ameliorated
myocardial damage after MI/R in WT animals, which was
accompanied by decreased leukocyte infiltration. Neutrophil
infiltration is one of the hallmarks of reperfusion injury [29],
perpetuating tissue injury in the acute phase of reperfusion
while being a prerequisite for myocardial wound healing
and scar formation. In neutrophils, however, RAGE has only
a minor role in the promotion of HMGB1-induced NF-𝜅B
activation as compared to TLR2 and TLR4 [16]. Furthermore,
preconditioning with HMGB1 renders THP-1 monocytes less
responsive to stimulation with TLR2 agonist lipoteichoic
acid, a mechanism independent of RAGE [30].
In TLR2−/− animals, which as previously reported [4],
showed reduced myocardial necrosis and leukocyte infiltra-
tion, no further protection could be observed after treatment
with Box A, which would have been expected if HMGB1
signalling was solely RAGE-dependent in MI/R [13]. This is
even more highlighted by the observation, that endogenous
HMGB1 release is significantly increased in these animals
after MI/R. A compensating alteration of RAGE or TLR9
expression in TLR2−/−myocardium could be excluded, while
a moderate up-regulation of TLR4 became evident in these
animals.
The recombinant HMGB1 preparation used in this study
could not augment myocardial necrosis in WT animals,
which is, however, in line with recent evidence questioning
the perception thatHMGB1 itself serves as a proinflammatory
mediator [31–34]. Unlike the recombinant HMGB1 used in
the pertinent study by Andrassy et al. showing aggravation
of myocardial necrosis after treatment with HMGB1 [13], the
recombinant HMGB1 preparation used in the present study
was a commercially available lipopolysaccharide-free prepa-
ration. This preparation was also tested in HL-1 cardiomy-
ocytes wherein it failed to induce proinflammatorymediators
(Tumour necrosis factor 𝛼, Interleukin-6, Chemokine (C-X-
Cmotif) ligand 2, data not shown). Accordingly, no effects of
HMGB1 treatmentwere observed inWTor TLR2−/− animals.
The question whether HMGB1 functions as a cytokine
itself or as a cofactor/chaperone for other DAMPs cannot be
answered by the present study. The data provided here, how-
ever, allow for the conclusion that successful infarct-sparing
therapies blocking HMGB1 in MI/R might be dependent on
the presence of TLR2. The latter might be of particular inter-
est for the development of therapeutic strategies targeting
HMGB1, because less functional TLR2 polymorphisms are
frequently found in theCaucasian population (9.4%) [23] and
in patients undergoing cardiac surgery (3.8%) [27]. TLR2−/−
animals show elevated HMGB1 plasma levels 24 hours after
MI/R as compared to WT. Similarly, heterozygous carri-
ers of the Arg753Gln polymorphism displayed significantly
increased serum HMGB1 levels on day 3 after CABG surgery
as compared to control patients, suggesting that this group
of patients might respond differently to HMGB1-targeting
therapy. This is even more intriguing since elevated HMGB1
plasma levels have been identified to be independently
associated withmortality and residual ventricular function in
ST-segment elevationmyocardial infarction treated by percu-
taneous coronary intervention (PCI) [35, 36], and carriers of
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Figure 3: Expression levels of HMGB1 and its receptors after MI/R (30min/24 hrs). (a) A moderate up-regulation of HMGB1 mRNA can be
detected in the area not at risk (ANAR) of TLR2−/− animals, (b) accompanied by increased HMGB1 plasma levels. Expression levels of RAGE
(c, d) or TLR9 (e) were not significantly different between genotypes while TLR2−/− animals showed an up-regulation of TLR4 mRNA (f)
compared to WT in ANAR and AR. ∗𝑃 < 0.05, ANAR area not at risk, AR area at risk.
the Arg753Gln polymorphism are at higher risk for coronary
restenosis after MI and PCI [24].
5. Conclusions
In conclusion this study contributes to our understanding of
the role of HMGB1 in myocardial ischemia and reperfusion.
Besides the known involvement of its receptor RAGE, we
here provide evidence for a role of TLR2 in mediating effects
of endogenous HMGB1 released during acute myocardial
ischemia and reperfusion.
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